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Objectives: Pertussis is endemic in the US despite recommendations for rou-
tine vaccination. Recent evidence suggests waning immunity among adolescents 
is one catalyst for the spread of disease. Although 89% of adolescents received 
Td/Tdap vaccine in 2012, little is known about coverage of pertussis containing 
vaccination specifically, or if Tdap is administered at age-appropriate times (age 
10 to 12 years). We sought to evaluate coverage and age-appropriate Tdap receipt 
among adolescents in the US. MethOds: Participant reported demographics and 
immunization provider reported vaccinations were analyzed from the 2010 and 
2011 National Immunization Survey-Teen. Among children aged 13 to 17 years, we 
assessed the proportion who received at least one dose of Tdap (coverage) and the 
age at administration (age-appropriate receipt). Among those who received Tdap, 
we estimated multivariable logistic regression models to identify factors associated 
with age-appropriate vaccination. Results: Between 2010 and 2011, the propor-
tion of adolescents who received at least one Tdap vaccination between the ages 
of 10 to 17 increased from 64.3% to 73.8%, respectively (p< 0.0001). Among those 
who received Tdap, 61.6% in 2010 to 71.3% in 2011 received age-appropriate vac-
cination (p< 0.0001). Among those who delayed Tdap vaccination, the mean age of 
vaccination was approximately 14 years in both 2010 and 2011. Among adolescents 
who received Tdap, having a mother with more than 12 years of education (OR= 1.2, 
p< 0.0001) increased the likelihood of age-appropriate vaccination. Whereas, not 
having an adolescent well-child visit (OR= 0.46, p< 0.0001), having multiple vacci-
nation providers (OR= 0.85, p< 0.0001), and having a gap in health insurance cover-
age (OR= 0.72, p= 0.0004) significantly decreased the likelihood of age-appropriate 
vaccination. cOnclusiOns: Coverage and age-appropriate receipt of Tdap among 
adolescents is suboptimal, yet improving. Overall, two-thirds of adolescents received 
Tdap, of which 29% to 38% received it after the recommended age, on average leaving 
two years during which pertussis immunity may have waned.
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Objectives: To assess persistence on protease inhibitors [PI; atazanavir/ritonavir 
(ATV±r), lopinavir/r (LPV/r), darunavir/r (DRV/r)]- or efavirenz (EFV)-based antiretro-
viral therapy (ART)] in the Women’s Interagency HIV Study (WIHS), a large, US, obser-
vational cohort. MethOds: This retrospective analysis of WIHS used bi-annually 
collected data from January 1998-April 2013. HIV+ women initiating ATV±r, LPV/r, 
DRV/r or EFV were followed until discontinuation of the index PI or EFV, dropout 
from cohort, or end of study period. Persistence on ATV±r, LPV/r, DRV/r or EFV over 
50 months stratified by prior ART experience (ART naive, 0-1 prior PI, ≥ 2 prior PIs) 
was analyzed using Kaplan-Meier curves. In the analysis, we considered patient 
baseline variables (demographics, co-morbidities, viral load, CD4, and depression/ 
quality of life and ART regimens used prior to initiating the index PI or EFV), and 
follow-up variables (adherence, reasons for ART discontinuation). Results: In total, 
661 women initiated ATV±r, 546 LPV/r, 203 DRV/r and 815 EFV-based regimens. Mean 
age was 41 years, > 50% were Black, > 15% were HCV+ and > 50% had prior illicit drug 
use. For women with no prior ART, persistence at 50 months was 54% for EFV, 53% 
for ATV±r, and 14% for LPV/r (P = 0.0015); DRV/r had unreliable data in ART-naïve 
due to small sample size). For ART exposed women with 0-1 PI, persistence was 64% 
for DRV/r, 50% for ATV±r, 49% for EFV, and 29% for LPV/r (P < 0.0001). For women 
with ≥ 2 prior PI exposure, persistence was 70% for DRV/r, 41% for ATV±r, 28% for 
LPV/r, and 23% for EFV (P < 0.0001). cOnclusiOns: Persistence differed among the 
ART regimens in analyses that stratified by prior ART/PI experience. Proportional 
hazards regression will be used to examine if case-mix differences contribute to 
these patterns.
PIN79
real-World PersIsTeNce WITh sINgle Versus mulTIPle TableT 
regImeNs For hIV-1 TreaTmeNT
Sweet D.E.1, Kim Y.2, Song J.3, Zhong Y.3, Signorovitch J.3
1The University of Kansas School of Medicine – Wichita, Wichita, KS, USA, 2Gilead Sciences, Inc., 
Foster City, CA, USA, 3Analysis Group, Inc., Boston, MA, USA
Objectives: Non-persistent use of any component of an antiretroviral (ARV) regi-
men can lead to viral replication and treatment resistance. We compared real-
world persistence between HIV-1 infected patients receiving once-daily single 
tablet regimens (STRs) versus multiple-tablet regimens (MTRs) using 7-year his-
tory in a claims database. In addition, we assessed whether initial MTR persis-
tence predicted long-term persistence comparable to an STR. MethOds: HIV-1 
infected patients filling ARV prescriptions after a 90-day washout were identified 
in a large claims database (07/2006-03/2013). Index regimens were classified as 
STRs (1 pill daily) or MTRs (≥ 2 pills daily). Persistence was measured as the time 
from starting the index regimen to the first 90-day prescription gap for any ARV 
in the index regimen, or to the first prescription for an ARV not in the index 
regimen. Persistence was compared between STRs and MTRs with a logrank test. 
Additionally, the subgroup persistent on MTRs for the first 6 months was compared 
to the full group receiving STRs and the subgroup persistent on STRs for the first 6 
months. Results: Among 3,590 patients who initiated ART, 1,909 (53%) patients 
Objectives: The study investigated the longitudinal effect of pharmacy manage-
ment programs on adherence rates for patients using dual therapy for the hepatitis 
C virus (HCV) within retail and central pharmacy channels. MethOds: This was a 
retrospective study of patients new to HCV therapy, who used either retail or central 
pharmacy channels to obtain their HCV prescriptions. Although the two channels 
had different operational structures, they provided similar patient management ser-
vices. The adherence metric was the proportion of days covered (PDC), as endorsed 
by the Pharmacy Quality Alliance. Active involvement with a patient management 
program for at least 90 days was examined as a predictor for adherence. Due to the 
different managed therapy models across channels, propensity scores were used 
to match patients for the retail analysis, and analysis of covariance was used for 
the central analysis. Results: Mean PDC rates for the retail patients improved 
significantly (16.2%, p < 0.0001) for patients managed at least 90 days compared to 
those less managed. Similarly, patients managed at least 90 days within the central 
distribution channel had significantly higher adherence rates (29.4%, p < 0.0001) 
than those who did not remain managed. Among retail patients managed at least 
90 days, the mean adherence level (77.9%) was comparable (i.e., not significantly 
different) to that of the central patients (76.8%). The proportion of patients who 
were adherent to medications (PDC ≥ 80%) indicated similar significant trends as 
for mean PDC. cOnclusiOns: Pharmacy services increased adherence to HCV dual 
therapy medications in both central and retail pharmacy channels, and reduced the 
difference in adherence between channels. Previous research has linked medica-
tion adherence to reduced viral loads from drug therapy, and improved clinical 
outcomes. Providing HCV pharmacy management programs that address patient 
adherence to therapy will likely improve the long-term health outcomes for these 
patients.
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bAckgROund: Compliance with HIV treatment guidelines has not been studied in 
a large sample of real-world patients. Objectives: Document the impact of guide-
lines and patient characteristics on adherence. MethOds: Prescription drug data 
from a national retail pharmacy chain were used to identify new episodes of HIV 
therapy initiated between January 1, 2008 and July 31, 2012. The mix of medications 
used as initial therapy was defined using a 4 days window following the fill date of 
the initial HIV prescription. All episodes were screened for 6 months of data with no 
prior HIV prescriptions and for one year of post data. Patient characteristics included 
age, gender, state of residence and health insurance type. Regimens were classified 
according to the United States (US) Department of Health and Human Services (DHHS) 
treatment guidelines. Adherence was measured as the proportion of days covered 
[PDC] and PDC≥ 90%. Results: 113,933 episodes met study criteria. Patients were 
predominately male and between ages 35 and 55. Average PDC was 41.4% and only 
16.2% of patients achieved PDC≥ 90%. Multivariate analyses found that adherence 
increased monotonically with age and with male gender. Nearly 43% of patients used 
a DHHS preferred regimen and achieved significantly better adherence. Patients were 
less adherent when ritonavir was added to the treatment regimen. Using the single 
tab DHHS preferred regimen increased the likelihood of achieving PDC≥ 90% [Odds 
ratio = 1.23; (1.16-1.30)]. Patients using non-DHHS guideline regimens were less likely 
to be adherent though their PDC increased monotonically with the number of drugs 
used. cOnclusiOns: The quality of HIV drug therapy in the US is mixed. While 59% 
of patients use a DHHS approved regimen, 30% of patients used only a single medi-
cation. Just over 16% of patients achieved a PDC of ≥ 90%. However, this goal is more 
likely to be achieved when prescribing follows treatment guidelines.
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Objectives: Elderly population has a higher chance of developing pneumococcal 
disease and is recommended to receive pneumococcal vaccination by government 
agencies around the world. In the U.S., CDC reports pneumococcal vaccination 
coverage in the elderly annually. However, the pneumococcal vaccination coverage 
in elderly outside of the U.S. is unclear. The objective of this study was to review 
published data on the current global pneumococcal vaccination. MethOds: A 
systematic literature review was conducted in PubMed/MEDLINE to identify stud-
ies published between 2011-2013 that have assessed pneumococcal vaccination 
coverage in elderly population aged 65 years or older. Results: Thirty-nine stud-
ies that assessed pneumococcal vaccination among elderly were identified, with 
16 from North America (NA), 11 from Western Europe (WE), 7 from Asia Pacific 
(AP), 3 from Latin America (LA), and 2 from the Middle East (ME). No studies were 
found in Eastern Europe (EE) and Africa. Around 70% of identified studies were 
from NA and WE, where most governments have recommended pneumococcal 
vaccines for elderly. While many countries in AP, LA, and EE have similar recom-
mendations, only a few countries have conducted studies to assess the vaccination 
coverage to explore the policy uptake. Limited countries in Africa and ME have 
national recommendations, which could be the reason why the related research 
has been scant. Overall, 15 studies explored pneumococcal vaccination for general 
older population, while the rest (n= 24) assessed coverage for elderly with certain 
conditions or sociodemographic characteristics, or in specific settings. Population-
based studies showed that the pneumococcal vaccination coverage in elderly 
ranged 49.8%-68.6% for NA (n= 5),36.4%-50.9% for WE (n= 2),18.4%-61.0% for AP 
(n= 5),8.7%-44.3% for LA (n= 2), and 72% for Israel (n= 1). cOnclusiOns: Limited 
data on pneumococcal vaccination in elderly were reported for countries in LA, AP, 
EE, ME, and Africa regions. Further studies that examine pneumococcal vaccina-
tion in these regions are needed to evaluate the implementation of related policy.
